OBJECTIVE - The aim of this study was to investigate whether diabetic patients carrying the Arg(972) insulin receptor substrate-1 (IRS-1) variant are at increased risk for secondary failure to sulfonylurea. RESEARCH DESIGN AND METHODS - A total of 477 unrelated Caucasian type 2 diabetic patients were recruited according to the following criteria: onset of diabetes after age 35 years, absence of ketonuria at diagnosis, and anti-GAD(-) antibody. Type 2 diabetes was diagnosed according to the American Diabetes Association criteria. Patients with secondary sulfonylurea failure were defined as those requiring insulin due to uncontrolled hyperglycemia (fasting plasma glucose >300 mg/dl) despite sulfonylurea-metformin combined therapy, appropriate diet, and absence of any conditions causing hyperglycemia. RESULTS - Of the total patients, 53 (11.1%) were heterozygous for the Arg(972) IRS-1 variant, 1 (0.2%) was homozygous, and the remainder (88.7%) were homozygous for the wild-type allele. The genotype frequency of the Arg(972) IRS-1 variant was 8.7% among diabetic patients well controlled with oral therapy and 16.7% among patients with secondary failure to sulfonylurea (odds ratio 2.1[95% Cl 1.18-3.70], P = 0.01). Adjustment for age, sex, BMI, metabolic control, age at diagnosis, duration of diabetes, and Pro12Ala polymorphism of peroxisome proliferator-activated receptor-gamma2 gene in a logistic regression analysis with secondary failure to sulfonylurea as a dependent variable did not change this association (2.0 [1.38-3.86], P = 0.038). CONCLUSIONS - These data demonstrate that the Arg(972) IRS-1 variant is associated with increased risk for secondary failure to sulfonylurea, thus representing a potential example of pharmacogenetics in type 2 diabetes.
Sesti, G., Marini, M.A., Cardellini, M., Sciacqua, A., Frontoni, S., Andreozzi, F., et al. (2004). The Arg972 variant in insulin receptor substrate-1 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. DIABETES CARE, 27(6), 1394-1398.
Tipologia: | Articolo su rivista | |
Citazione: | Sesti, G., Marini, M.A., Cardellini, M., Sciacqua, A., Frontoni, S., Andreozzi, F., et al. (2004). The Arg972 variant in insulin receptor substrate-1 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. DIABETES CARE, 27(6), 1394-1398. | |
IF: | Con Impact Factor ISI | |
Lingua: | English | |
Settore Scientifico Disciplinare: | Settore MED/13 - Endocrinologia | |
Revisione (peer review): | Sì, ma tipo non specificato | |
Tipo: | Articolo | |
Rilevanza: | Rilevanza internazionale | |
Digital Object Identifier (DOI): | http://dx.doi.org/10.2337/diacare.27.6.1394 | |
Stato di pubblicazione: | Pubblicato | |
Data di pubblicazione: | 2004 | |
Titolo: | The Arg972 variant in insulin receptor substrate-1 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes | |
Autori: | ||
Autori: | Sesti, G; Marini, MA; Cardellini, M; Sciacqua, A; Frontoni, S; Andreozzi, F; Irace, C; Lauro, D; Gnasso, A; Federici, M; Perticone, F; Lauro, R | |
Appare nelle tipologie: | 01 - Articolo su rivista |